Stock Traders Buy Large Volume of Compass Therapeutics Call Options (NASDAQ:CMPX)

Key Points

• Unusually high call-option activity: Traders bought 4,010 Compass Therapeutics call options, 115% above the average volume of 1,869 contracts.
• Shares remain under pressure: CMPX traded at $0.79, near its 52-week low of $0.73, and recently reported a quarterly loss of $0.13 per share versus analysts’ expected loss of $0.11.
• Analyst outlook is cautiously positive: The stock has a consensus “Moderate Buy” rating and a $10.25 price target, although analyst opinions range from Strong Buy to Sell. Institutional investors own 68.43% of the company.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw unusually large options trading on Friday. Traders bought 4,010 call options on the company. This represents an increase of 115% compared to the average volume of 1,869 call options.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX traded up $0.03 during trading on Friday, hitting $0.79. 2,916,330 shares of the company traded hands, compared to its average volume of 4,603,215. Compass Therapeutics has a fifty-two week low of $0.73 and a fifty-two week high of $6.88. The business's fifty day moving average is $1.49 and its 200 day moving average is $3.25. The firm has a market capitalization of $141.64 million, a price-to-earnings ratio of -1.97 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, analysts predict that Compass Therapeutics will post -0.47 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on CMPX shares. Guggenheim reduced their price objective on Compass Therapeutics to $4.00 and set a "buy" rating for the company in a research note on Wednesday, September 23rd. Lifesci Capital cut shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 22nd. Piper Sandler lifted their target price on Compass Therapeutics from $4.00 to $6.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Wedbush set a $4.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Finally, Citigroup reissued a "market outperform" rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.25.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State of Alaska Department of Revenue acquired a new position in Compass Therapeutics in the third quarter valued at $104,000. Sequoia Financial Advisors LLC boosted its position in shares of Compass Therapeutics by 189.5% during the second quarter. Sequoia Financial Advisors LLC now owns 44,980 shares of the company's stock worth $99,000 after buying an additional 29,445 shares during the period. WINTON GROUP Ltd acquired a new stake in Compass Therapeutics in the second quarter worth approximately $55,000. Squarepoint Ops LLC lifted its position in shares of Compass Therapeutics by 1,906.9% during the 2nd quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company's stock valued at $2,206,000 after acquiring an additional 957,305 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Compass Therapeutics in the second quarter worth $71,000. Institutional investors and hedge funds own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company's research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.